A first-in-human phase 1 trial of NX-2127, a first-in-class oral BTK degrader with IMiD-like activity, in patients with relapsed and refractory B-cell malignancies Meeting Abstract
| Authors: | Mato, A.; Danilov, A. V.; Patel, M. R.; Tees, M. T.; Flinn, I. W.; Ai, W. Z.; Patel, K.; Wang, M.; O'Brien, S. M.; Nandakumar, S.; Tan, M.; Meredith, E.; Gessner, M.; Kim, S. Y.; Wiestner, A.; Wierda, W. G. |
| Abstract Title: | A first-in-human phase 1 trial of NX-2127, a first-in-class oral BTK degrader with IMiD-like activity, in patients with relapsed and refractory B-cell malignancies |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680305080 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.TPS7581 |
| Notes: | Meeting Abstract: TPS7581 -- Meeting also held virtually -- Source: Wos |
